Compare Pfizer Inc (PFE) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

SPUS trades at $56.32, down 0.23% on the day, with a bearish technical outlook from moving averages and oscillators. Key support is at $56, with resistance at $57. The stock's financial ratios, including P/E and P/S, are not available in the provided data. Recent corporate actions include small dividend payments scheduled for mid-2026, indicating a shareholder return focus.

The outlook for SPUS is cautious due to weak technical signals and limited fundamental data visibility. Investment opportunities may lie in its dividend strategy, but risks include market volatility and lack of current financial metrics. Investors should seek updated earnings reports for a clearer fundamental picture before considering a position.